HOME >> BIOLOGY >> NEWS
Other highlights from the July 10 JNCI

Nanobubbles Deliver Targeted Cancer Drugs Using Ultrasound

A new targeted drug delivery method uses ultrasound to image tumors, while also releasing the drug from nanobubbles into the tumor.

Cancer drugs can be targeted to tumors by delivering them in packets of nanoparticles, then releasing them with ultrasound. But this approach can be difficult because it requires a way to image the tumor prior to treatment.

Natalya Rapoport, Ph.D., D.Sc., of the University of Utah in Salt Lake City and colleagues describe a new method of drug delivery that may address this problem. Nanobubbles filled with the chemotherapy drug doxorubicin were injected into mice. The bubbles accumulated in the tumors, where they combined to form larger microbubbles. When exposed to ultrasound, the bubbles generated echoes, which made it possible to image the tumor. The sound energy from the ultrasound popped the bubbles, releasing the drug. In mice treated with this method, the nanobubbles were more effective at blocking tumor growth than other nanoparticle delivery methods.

Microbubble formulations have been developed for combining ultrasonic tumor imaging and ultrasound-enhanced chemotherapeutic treatment, the authors write.

Contact: Natalya Rapoport, natasha.rapoport@m.cc.utah.edu, (801) 581-8990


Gene May Promote Resistance to Chemotherapy Drugs

A gene known as HDAC1 may be a good target for drugs to treat multidrug-resistant neuroblastoma, a cancer that develops in immature nerve cells and is prevalent in children.

Drug resistance could explain why about 50% of high-risk neuroblastoma patients die of the disease. Nino Keshelava, M.D., of Childrens Hospital Los Angeles and colleagues studied several human neuroblastoma cell lines to identify genes that cause drug resistance.

They found that HDAC1 was overexpressed in m
'"/>

Contact: Liz Savage
jncimedia@oxfordjournals.org
301-841-1287
Journal of the National Cancer Institute
10-Jul-2007


Page: 1 2

Related biology news :

1. Other highlights in the Aug. 7 JNCI
2. Other highlights in the July 24 JNCI
3. Other highlights in JNCI, June 26
4. Other highlights in JNCI, June 12
5. Other highlights from the June 6 JNCI
6. Other highlights in the May 16 JNCI
7. Other highlights from the April 18 Journal of the National Cancer Institute
8. Other highlights from the March 21 JNCI
9. Other highlights in the March 7 JNCI
10. Other highlights in the Feb. 21 JNCI
11. Other highlights in the Jan. 17 JNCI

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/13/2019)... ... June 13, 2019 , ... KICVentures announced today its plans ... Orthopedic and Pain Management-Driven ASC Conference in Chicago on Thursday, June 13th at 6:30 ... Dr. Chicago, IL in the 3rd floor Ticino Hospitality room in space #74T. , ...
(Date:6/11/2019)... ... 10, 2019 , ... Improved Pharma LLC announces the publication of “Predictive and ... The article was published online on April 29th, 2019. The authors are Stephen ... Chen of Purdue University. , The article is the most recent addition to a ...
(Date:6/6/2019)... ... June 05, 2019 , ... Ziegler, a ... advisor to Pathologists Bio-Medical Laboratories (PBM) on its recent acquisition by PathGroup. ... that provides services to more than one dozen hospitals and surgery centers in ...
Breaking Biology News(10 mins):
(Date:6/18/2019)... ... June 17, 2019 , ... ... entered into an agreement for production and manufacturing of GMP-grade adeno-associated virus (AAV) ... rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP) and IC-200 for the treatment of BEST1 ...
(Date:6/11/2019)... CITY, Calif. (PRWEB) , ... June 10, 2019 ... ... (IOPP) today announced IOPP will add 80 of its scientific journals to DeepDyve’s ... of physics-related content to DeepDyve’s continually expanding library of more than 20 million ...
(Date:5/31/2019)... ... May 29, 2019 , ... For many years, the primary forms ... cancer demand breakthrough therapies. Advances in immuno-oncology have led to the advent of Chimeric ... with engineered T cell receptors known as “CARs”. The CAR enables the final product ...
(Date:5/22/2019)... ... 22, 2019 , ... Artemis (formerly Agrilyst), the leading enterprise Cultivation ... round co-led by Astanor Ventures and Talis Capital with participation ... iSelect Fund . The company has raised $11.75m to date and will use the ...
Breaking Biology Technology:
Cached News: